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Original Research Paper
Development of a gait module to complement the
12-item Multiple Sclerosis Walking Scale: a mixed
methods study
Sara Strzok, Sophie Cleanthous, Farrah Pompilus, Stefan J Cano, Patrick Marquis, Stanley Cohan,
Myla D Goldman, Kiren Kresa-Reahl , Jennifer Petrillo and Carmen Castrillo-Viguera,
Diego Cadavid and Shih-Yin Chen
Abstract
Background and objective: The 12-item Multiple Sclerosis Walking Scale (MSWS-12) is a patient-
reported outcome instrument that quantifies the progressive loss of walking ability from the patient
perspective. However, previous psychometric analyses indicated floor and ceiling effects across the
multiple sclerosis severity spectrum. This study aimed to address floor effects by creating a gait module
that can be used in conjunction with the MSWS-12 for better measurement of treatment benefit in
the higher functioning multiple sclerosis population.
Methods:We used a step-wise mixed methods study design, with relapsing–remitting multiple sclerosis
patients (wave 1, n=88; wave 2, n=30), combining qualitative (concept elicitation and cognitive debrief-
ing interviews) and quantitative (Rasch Measurement Theory) data collection and analytical techniques
and consultation interviews with three neurologists specializing in multiple sclerosis.
Results: Thirty-seven walking ability concepts were identified, and a five-domain conceptual frame-
work was created. Draft items were generated and refined with patient and neurologist input. Draft
items covered gait-related concepts such as dragging, shuffling, limping, tripping and falling. Rasch
measurement theory psychometric analysis indicated administering MSWS-12 plus gait items improved
measurement precision in targeted populations with better walking ability.
Conclusion: Study findings indicate that new gait items could improve sensitivity to detect clinical
change in walking ability for higher functioning multiple sclerosis patients.
Keywords: Walking ability, multiple sclerosis, MSWS-12, patient-reported outcomes, Rasch measure-
ment theory
Date received: 31 January 2018; Revised received 30 April 2018; accepted: 17 May 2018
Introduction
Loss of walking ability is a hallmark of functional
decline in multiple sclerosis (MS),1 and is important
to monitor as it signals changes in disease severity
and progression.2 Recent developments regarding
diagnosis and treatment also warrant consideration.
MS patients are being diagnosed earlier in the
disease course3 and are maintaining function,
particularly walking ability, for longer periods of
time.4 Furthermore, emerging therapies, particularly
remyelinating therapies, can potentially improve
walking ability.5,6
In clinical trials, walking ability is often assessed
using performance outcome measures, including
the timed 25-foot walk and the six-minute walk
test.7 However, these measures have a limited con-
nection to functional ability and the impact on
patients’ day-to-day lives. Because including
patient-reported outcome (PRO) measures in clinical
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trials is increasingly important from a development
and regulatory perspective,8 we need robust, well
targeted PRO measures of walking ability to capture
this information, particularly in patients with more
mild walking dysfunction.
The Multiple Sclerosis Walking Scale 12-item
(MSWS-12) is a PRO measure that is widely used
to address this need.7 MSWS-12 comprises 12 items
describing the impact of MS on walking, identified
from a larger pool of 141 items derived from
patients, clinicians and literature about the ‘health
impact of MS.9 MSWS-12 was psychometrically
validated using classic test theory methods.
However, more recent research using modern test
theory methods (Rasch Measurement Theory;
RMT) detected disordering in the instrument’s
response categories and poor targeting at the floor
of the scale,10 suggesting that MSWS-12 may be less
sensitive to change in patients with more subtle def-
icits in walking ability. In addition, like many legacy
PRO measures developed prior to regulatory guid-
ance emphasizing conceptual clarity,11 MSWS-12
was not developed based on a well-defined, compre-
hensive conceptual framework.9
The objective of this research was to address the
floor effect of the MSWS-12 and its sensitivity to
change in walking ability in early stage relapsing–
remitting multiple sclerosis (RRMS) patients.
In alignment with regulatory and professional guid-
ance for addressing measurement issues in existing
PRO measures,12,13 we conducted patient-centered
research to develop new items that measure symp-
toms and functional impact of walking limitations in




We performed patient-centered research to expand
and refine our understanding of the concept of inter-
est – walking ability in less disabled people with
MS – to create a conceptual framework of treatment
benefit and pilot test potential new items. The
research comprised two waves of patient interviews
and consultation with three clinical neurologists in
MS at each stage. Interviews collected both qualita-
tive (discussion) and quantitative (PRO response)
data, which allowed us to conduct a mixed methods
analysis (see Figure 1). In psychometric research,
‘mixed methods’ refers to the synthesis of qualita-
tive and quantitative methods to identify, define
and operationalize PRO instruments as measures
Interviews with n=88 RRMS paents
Walking concept elicitaon
Complete & debrief original MSWS-12
Mixed methods analysis
Qualitave coding, MS specialist feedback
Quantave RMT Analysis
Dra item development
Interviews with n=30 RRMS paents
Test (debrief) new items 
Complete original MSWS-12 + new items to 
enable small scale analysis
Mixed methods analysis
Qualitave coding, MS specialist feedback
Quantave RMT Analysis
2 rounds item refinement
37 walking concepts
5-domain conceptual framework
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of a given concept of interest in a specific context
of use.14
Study population and recruitment process
Institutional review board approval was obtained,
and participants provided written informed consent.
Early RRMS patients were recruited through the
study sponsor’s patient services department and
through a social media site for MS patients.
Eligible patients were diagnose d with RRMS
within the last 2 years and had a patient determined
disease steps (PDSS)15 score of 0–1 (no to mild dis-
ability). This PDDS range coincides with the
Expanded Disability Status Scale (EDSS) 0–2
levels,16 in which recent research indicated limita-
tions in the MSWS-12’s measurement range and pre-
cision (i.e. floor effects).
Patient interviews
Two waves of patient interviews were conducted.
Wave 1 concept elicitation interviews followed a
semistructured interview guide that fostered discus-
sion around symptoms and impacts experienced in
early MS. Patients also completed and discussed the
MSWS-12. Data from wave 1 interviews allowed us
to identify aspects of walking ability relevant to this
sample and to create a conceptual framework
to organize meaningful aspects of walking ability
that can be used to evaluate treatment benefit in
the context of clinical research.8 From these data,
we generated new items to address the floor effect
in the MSWS-12.
Wave 2 interviews were cognitive debriefing inter-
views to establish relevance, clarity and ease of com-
pletion of the draft items that were generated after
wave 1. Patients followed a ‘think aloud’ process,
completing the items while explaining their thought
process and noting any problems or ambiguities in
these items.17 Patients also completed the MSWS-12
and new items to provide quantitative data for
RMT analysis.
All interviews were conducted over the telephone;
the MSWS-12 and new draft items were displayed
on patients’ computer screens, and item responses
were captured by means of an online platform.
Interviews were audio-recorded and transcribed.
Three neurologists specializing in MS (SC, MDG,
KKR) were consulted after each of the waves
to confirm the clinical relevance of the concepts
elicited and to provide feedback on the emerging
conceptual framework and items.
Data analysis
Wave 1 qualitative analysis: concept elicitation.
Transcripts were analyzed thematically18 through
detailed line-by-line coding,19 using ATLAS.ti
software.20 Coding was targeted to capture walking
ability concepts. Codes and quotations were induc-
tively categorized into overarching domains. Each
code was compared with the rest of the data to
create analytical domains and subdomains.
Saturation, or the point in the data collection process
when no new concept-relevant information emerges
from additional qualitative data,21 was assessed by
ordering interviews chronologically, grouping them
into quantiles and comparing concepts emerging by
each sequential quantile.
Development of conceptual framework, concept
mapping to MSWS-12 and item generation.
Patient-generated walking ability concepts were
inductively categorized into domains to create a con-
ceptual framework of walking ability in MS.
Concepts and domains were mapped against the
MSWS-12 to identify concepts important to patients
that were not in the existing instrument.
Item generation followed item construction
principles,11,22–24 aiming to have an adequate range
of items to cover the selected domain of walking
ability. Item construction used as many of the
patients’ own words as possible.
Wave 2 qualitative analysis: cognitive debriefing.
This analysis aimed to identify wording ambiguities
and assess relevance and acceptability in relation to
each new item, response scale and set of instructions.
Additional items suggested by wave 2 participants
that could further expand the measurement of walking
disability in early RRMS were also explored.17
Quantitative data analysis. Small-scale RMT analy-
sis was performed using MSWS-12 data from wave 1
and MSWS-12 plus complimentary items data from
wave 2 using RUMM 2030.25 RMT analysis was
performed on the original PRO instrument scoring
and on the revised scale structure proposed following
preliminary analysis.26 RMT analysis compares
observed data against the stringent criteria of the
Rasch model, aiming to assess the sample-to-scale





A total of 118 patients with RRMS participated in
this research study (n=88 wave 1; n=30 wave 2).
Difficulties with walking were reported by 78%
(n=69) of wave 1 patients at screening; all patients
in wave 2 reported walking difficulty. Most patients
were women (wave 1, 74%; wave 2, 80%), and the
sample in both waves was evenly divided between
PDDS 0 (50%) and 1 (50%) (see Table 1).
Wave 1: concept elicitation. Patients reported 37
unique concepts related to walking ability. Table 2
lists these concepts, while Table 3 provides exem-
plar quotes illustrating walking concepts. Patients
described decreasing walking capacity in speed,
distance or duration that varied based on the walking
context, such as stairs or unfamilar terrain. They also
discussed adapations they employed to deal with
walking problems such as leaning on furniture
or walls and concentrating when walking. Patients
further described their walking ability in terms of
gait problems, including shuffling, stumbling, trip-
ping and falling. These higher functioning patients
reported that while the walking issues they experi-
enced on a day-to-day basis were relatively minor,
they affected their quality of life. Most patients
described proactively limiting activities such as
shopping, walking with friends, hiking on rough
terrain, or walking long distances based on concerns
about their walking ability. Patients explained that
their walking ability was usually severely impacted
during flares; on a day-to-day basis, walking could













PDSS score (N, %)
0 – normal 44 (50%) 12 (41.4%) 15 (50.0%)
1 – mild disability 44 (50%) 17 (58.6%) 15 (50.0%)
Age in years
Mean (SD) 40.0 (8.72) 38.34 (8.62) 38.9 (7.89)
Gender (N, %)
Male 23 (26.1%) 8 (27.6%) 6 (20.0%)
Female 65 (73.9%) 21 (72.4%) 24 (80.0%)
Race/ethnicity (N, %)
White 76 (86.4%) 24 (82.8%) 24 (80.0%)
Asian 1 (1.1%) 0 (0.0%) 0 (0.0%)
Black/African-American 5 (5.7%) 3 (10.3%) 4 (13.3%)
Hispanic/Latino 5 (5.7%) 2 (6.9%) 1 (3.3%)
Mixed race or ‘other’ 1 (1.1%) 0 (0.0%) 1 (3.3%)
Education (N, %)
High school 11 (12.5%) 1 (3.4%) 0 (0.0%)
Some college/AA degree
Trade certification 28 (31.8%) 13 (44.8%) 13 (43.3%)
Bachelor’s degree 32 (36.4%) 13 (44.8%) 8 (26.7%)
Postgraduate degree 17 (19.3%) 2 (6.9%) 9 (30.0%)
Employment statusa (N, %)
Full time 57 (64.8%) 19 (65.5%) 20 (66.6%)
Part time 14 (15.9%) 6 (20.7%) 3 (10.0%)
Not employed 10 (11.4%) 2 (6.9%) 7 (23.3%)
Student 2 (2.2%) 1 (3.4%) 1 (3.3%)
Homemaker 5 (5.7%) 2 (6.9%) 1 (3.3%)
aCounts not mutually exclusive; some patients reported more than one employment status.
RMT: Rasch measurement theory.
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be affected by weakness, neuromuscular symptoms
(e.g. tremor, spasm, numbness), fatigue and fatiga-
bility, proprioceptive and vestibular problems
and pain.
Saturation analysis found that 33 of 37 of the initial-
ly identified walking-related concepts arose within
the first 40 interviews. The four concepts elicited in
the remaining 48 interviews were similar to concepts
Table 2. Conceptual framework of walking ability in early RRMS, mapping to MSWS-12.
Adaptation
Balance and
coordination Capacity Context Gait



































 Knee gives out
 Leaning while walking
 Leg drag








 Indicates concept covered by MSWS-12.
aConcept elicited similar to MSWS-12 item 11 (affected how smoothly you walk).
RRMS: relapsing–remitting multiple sclerosis; MSWS-12: Multiple Sclerosis Walking Scale 12-item.
Table 3. Examples of patient descriptions of walking concepts.
Concept codes Example quotes
Locking extremities-
Stairs
It was more my leg would just kind of lock up. It was
particularly scary if I was going down the stairs.
Leg gives out I just got out of bed that morning, just as normal, and my
right leg just gave out. There was no pressure. It literally
just came from under me.
Standing balance Even just regular standing I would rather stand against a




But if I’m in a new place or I’m walking – for example,
across a parking lot, and I know a curb’s coming up, and
I’m looking. Any kind of terrain I don’t know, I have to
really – I concentrate and make sure I don’t stumble over
anything, because I’m always concentrating on making
sure I don’t fall.
Walking distance Walking. I have a trail behind my house that I walk every




derived from the first 40 interviews, indicating that
interviews produced a comprehensive picture of
walking-related concepts in higher functioning
patients with RRMS (see Table 4).
Conceptual framework, concept mapping to MSWS-
12 and item generation. To understand better the
impact on walking ability in MS and to inform a
conceptually clear measurement strategy for gener-
ating new items, concepts related to walking ability
were inductively categorized into five conceptual
domains (see Table 2):
• Adaptation: methods patients employ to adapt to
walking limitations;
• Balance and coordination: problems remaining
upright and steady;
• Capacity: limitations on the ability to walk, run,
or stand;
• Context: limitations on walking in certain
environments;
• Gait: problems reported with the manner
of walking.
Elicited concepts were then mapped to the MSWS-
12 to determine its conceptual coverage and identify
gaps. Of the 37 concepts elicited from higher func-
tioning RRMS patients, 28 were not assessed by
items of the MSWS-12 (see Table 2).
At this stage, item development was informed by
consultation with clinicians specializing in MS
and reference to the conceptual framework. First,
clinicians reviewed the conceptual framework and
walking concepts elicited from patients to determine
their suitability for extending the measurement
range of the MSWS-12 for patients with less
severe disability. Of the 28 concepts not included
in the MSWS-12, 13 were endorsed by two of the
three clinical experts as additional items to extend
the range of the MSWS-12: bending, crouching, rais-
ing leg/foot, drop foot, escalators, foot drag, leaning
while walking, leg gives out, rising from sitting/low
position, shuffling, tripping, walking duration and
concentrating while walking.
Clinician recommendations were then examined
considering gaps in MSWS-12 coverage and with
reference to the walking conceptual framework.
MSWS-12 does not offer comprehensive coverage
in any of the five domains of walking except adap-
tation. While all five domains within the walking
conceptual framework could be developed into dis-
tinct MS walking scales, developing gait items
appeared to provide the best opportunity to address
a gap in MSWS-12 coverage. This could also
enhance measurement of treatment benefit in less
disabled patients. MSWS-12 offers only one gait
item, ‘affected how smoothly you walk’, most sim-
ilar to descriptions of the ‘gait problems’ concept
elicited in interviews. Given that two of three clini-
cians endorsed six gait concepts (drop foot, foot
drag, leaning while walking, leg gives out, shuffling
and tripping) as relevant for higher functioning
patients, and an additional five concepts (drop foot,
leg drag, foot drag, toe drag, limp) as more relevant
for lower functioning patients, patient-elicited con-
cepts in this domain offered the potential to develop
items that could assess walking ability across the
broad range of MS severity.
Gait items were developed in alignment with best
practices for item development. Gait concepts were
assessed in light of clinician feedback, patient com-
ments, redundancies with existing MSWS-12 items,
potential item formulation problems (e.g. ‘double-
barreled’ items assessing more than one domain or
describing more than one task) and potential to
extend the measurement of the concept of interest.
Nine draft gait items were developed, with response
options and instructions formatted to complement
the MSWS-12 (see items 1–9, Table 5).
Wave 2: cognitive debriefing. Debriefing the nine
draft gait items with 30 early RRMS patients dem-
onstrated that overall these items were relevant, well
understood and acceptable to patients. Some con-
cerns were identified with items 02, 03 and 05.
Item 05 (be clumsy) presented the most interpreta-
tion difficulty; half the patient sample reported
that they considered upper limb clumsiness when
responding to this item. Two patients stated that
items 02 (legs give out) and 03 (legs lock up)
Table 4. Saturation of walking concepts (n¼37).
Interview 1–10 11–20 21–30 31–40 41–50 51–60 61–70 71–80 81–88
Number of
concepts
22 7 1 3 0 0 2 1 1
Multiple Sclerosis Journal–Experimental, Translational and Clinical
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were the same; an additional three patients stated
they did not understand what was meant by ‘lock
up’. Some patients suggested adding clarifying
wording to item 02 (legs or knees give out) including
‘losing control’, ‘buckling’, or ‘weakness’. To clar-
ify item 03 (legs lock up), two patients suggested
specifying which part of the leg locks up. Patients
were also asked whether any important questions
were missing from the gait measure; one patient
suggested adding an item on walking to the side
instead of in a straight line.
Final gait items. Clinicians reviewed patient feed-
back on the draft gait items and suggested item revi-
sions and potential additions. Based on patient and
clinician feedback, three gait items were revised for
better comprehension (item 02, legs or knees give
out; item 03, legs lock up; item 05, be clumsy) and
one new item (item 10, trouble walking in a straight
line) was added (see Table 5).
Quantitative data analysis. Analysis of MSWS-12
data from wave 1 indicated that sample-to-scale tar-
geting of the scale was suboptimal. Many items
appear not relevant for the sample as there are
no measurements on the right-hand side of the con-
tinuum (ceiling: worse walking ability); whereas
measurement for some people on the left (floor:
better walking ability) is not matched by any items
of equivalent difficulty in relation to walking
(see Figure 2).
Combining MSWS-12 and gait items resulted in
better targeting to the early MS sample (Figure 2
(b)). The person-item threshold plot of the combined
scales indicates that all but three of the new gait items
(legs lock, shuffle and limp) sit on the lower end of
the continuum (better walking ability) and therefore
improve MSWS-12 targeting on the floor of the scale.
Adding new gait items increased relative coverage of
the range of walking ability measured by the scale in
this sample to 74% from 70%. Increased coverage
Table 5. MSWS-12 and gait items.
MSWS-12 items
01 Limited your ability to walk?
02 Limited your ability to run?
03 Limited your ability to climb up and down stairs?
04 Made it more difficult to stand while doing things?
05 Limited your balance while standing or walking?
06 Limited how far you are able to walk?
07 Increased the effort needed for you to walk?
08 Made it necessary to use support when walking indoors (e.g. holding
onto furniture, using a cane, etc.)?
09 Made it necessary to use support when walking outdoors (e.g. using
a cane, a walker, etc.)?
10 Slowed down your walking?
11 Affected how smoothly you walk?
12 Made you concentrate on your walking?
Gait items
01 Caused you to drag your legs or your feet?
02 Caused your knees or legs to give out, buckle or collapse?
03 Caused your legs to become stiff or lock up?
04 Caused you to bump into things?
05 Caused you to be clumsy when you walk?
06 Caused you to shuffle?
07 Caused you to walk with a limp?
08 Caused you to trip?
09 Caused you to fall?
10 Caused you to have trouble walking in a straight line?
Wording in bold revised or added after wave 2 interviews based on patient and clini-
cian feedback.
MSWS-12: Multiple Sclerosis Walking Scale 12-item.
Strzok et al.
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improves a scale’s precision and sensitivity associated
with measurement, as evidenced by the sum and aver-
age standard error scores associated with person esti-
mates that decreased from 18.29 to 13.657 and 0.61 to
0.46 respectively.
No item misfit was identified; all items displayed fit
residuals within recommended ranges and none of the
items displayed significant chi-square correlations.
However, the five-level response scale only worked
as intended for 11 of 21 items, suggesting patients
may have had difficulty discriminating among the
five response options. In addition, 13 pairs of items
displayed residual correlations above the recom-
mended level (>0.3), suggesting possible dependency
between items, which can impact true reliability.
Despite this, the reliability of the combined item
sets with and without extremes was good (PSI 0.90/
0.90) and person misfit was low (n=3; 10%). This
suggests good measurement precision in a good qual-
ity dataset. Figure 2 illustrates the improved sample-
to-scale targeting of MSWS-12 plus gait items.
Discussion and conclusions
The patient’s perspective is a central part of clinical
research as evidenced by the recently published 21st
Century Cures Act 2016, which emphasizes patient-
centered outcomes.29 In addition, well defined and
reliable PRO instruments have been considered
essential by the US Food and Drug Administration
for over a decade.11,12 Walking is a central concept
of interest for MS clinical trials. While its objective
measurement is vital, the patient’s real-world expe-
rience needs to be integrated to provide meaning and
context to standardized walking assessments.
A notable example is the AMPYRA (dalfampridine)
label, in which the MSWS-12 was used to provide
meaning to the results of the timed 25-foot walk.30
In this study, we have begun to address the issues
around floor effects previously identified in the
MSWS-12, and thus improve the potential to
detect therapeutic effects in clinical trials, research
and ultimately, practice. Our study, which bridges
the 12 original MSWS items with 10 new gait
items, demonstrates one way to improve targeting
and sensitivity to change across a wider range of
MS severity. This multi-phase, mixed methods
study (together with companion studies presented
elsewhere)31,32 addresses the knowledge and mea-
surement gaps around the symptom experience of
higher functioning MS patients, presenting a clearer
picture of the entire experience of patients affected
by MS from early diagnosis onwards.
Our patient-centered research with 88 patients
resulted in a rich pool of walking concepts relevant
in early RRMS, from which a five-domain conceptual
framework of walking ability in MS was generated.
Because it had the best potential to address concepts
not included in the MSWS-12, we chose the gait
Figure 2. Sample-to-scale targeting. This figure provides a direct comparison of walking ability within the sample and
within the scale items. The upper histograms (pink blocks) represent the sample distribution and the lower histograms
(blue blocks) the scale item threshold distribution plotted on the same interval metric continuum of walking ability.
(a) Sample-to-scale targeting of the original MSWS-12 items and (b) the improvements to the match between sample and
scale targeting introduced by merging the original MSWS-12 with the gait module items. Sample measurements falling
off the 0–100 range of the scale indicate patients for whom the scale remains too easy.
Multiple Sclerosis Journal–Experimental, Translational and Clinical
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domain for item development. Ten candidate items
were produced to enhance the measurement of walk-
ing ability in MS, particularly in higher functioning
patients with better walking ability. Clinical neurolo-
gists helped ensure that item development focused on
the most clinically relevant items to measure walking
ability within this domain. Wave 2 interviews with 30
additional patients confirmed the relevance and
understanding of the new items and provided evi-
dence used to revise and refine the items.
Preliminary psychometric analysis of the MSWS-12
plus new items suggests improved targeting in this
higher functioning RRMS sample, with reduced
floor effects and greater precision in the ability to
discriminate different levels of walking ability.
Importantly, the item map of the combined scale indi-
cates that all but three of the new gait items (legs lock
up, shuffle and limp) sit on the lower end of the con-
tinuum (better walking ability), results that align with
the clinical assessment of the difficulty or severity of
these items. Thus when administered together with
MSWS-12, gait items improve the MSWS-12’s
scale targeting on the lower end of the scale, and
importantly, results indicate our proposed gait
module can be used as a standalone PRO instrument.
Findings should be interpreted with consideration of
the study’s limitations. A new item (item 10, trouble
walking in a straight line) was added after wave 2
interviews and clinician discussions; no performance
data are available for this item. Recruitment method-
ology dictated that inclusion criteria were based on
self-report information rather than a clinically con-
firmed diagnosis of RRMS. In addition, while prelim-
inary psychometric results are promising, the small
sample size and targeted mild disability population
for the RMT analysis require that these results be
interpreted with caution. Potential issues relating to
thresholds and dependency should be revisited in
larger, broader samples to decide on the best steps
forward. Additional analysis in a larger, clinically
defined sample would help confirm the validity and
generalizability of these findings as well as the new
items’ measurement properties. Finally, the MSWS-
12 and gait item stems (‘In the past two weeks, how
much has your MS . . .’) are simple and walking
descriptions are brief, presenting low cognitive
burden. However, given that the enhanced conceptual
coverage in higher functioning patients is achieved by
administering 10 items in addition to the MSWS-12
items, it may be worthwhile to explore the time
needed to complete the gait items in future studies.
Created using best practices for PRO item develop-
ment, the new gait items are potentially well suited
to measure gait ability across the spectrum of MS,
while specifically addressing measurement issues in
less disabled patients. Greater sensitivity to change
in this higher functioning population will allow more
accurate measurement of walking disability progres-
sion and of reversal of disability when it occurs.
Capturing this experience of walking ability enriches
our understanding of functioning in the MS popula-
tion represented now and enhances the likelihood of
understanding the potential benefits of emerging
therapies that may halt, or even reverse, early dis-
ease progression. Next steps include a full validation
study to understand the psychometric properties of
the overall item set across a broad MS population.
Following that, additional modules covering the
remaining four domains (adaptation, balance and
coordination, capacity and context) could be devel-
oped using a similar mixed methods process.
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